Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a biotechnology startup founded in 2015 and based in the United States. The company is dedicated to translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis utilizes its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, to target biological imbalances in the brain for both rare and prevalent neurological disorders. With a vision to reshape the human condition, Praxis aims to develop high-impact medicines to improve the lives of patients and families affected by complex brain disorders. Its focus on understanding shared biological targets and circuits in the brain has attracted significant attention and investment. In March 28, 2024, the company received a substantial $200.00M Post-IPO Equity investment, reflecting growing confidence in Praxis' innovative approach to addressing neurological disorders. As the era of genetic neuroscience arrives, Praxis Precision Medicines is poised to make a significant impact in the field of precision medicine.